Live Quote · NASDAQTTNPHealthcare· Biotechnology

Titan Pharmaceuticals, Inc.

$2.34 11.36%($-0.30)
TickerSpark Score
45/100
Weak
56
Valuation
40
Profitability
15
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TTNP research report →

52-Week Range0% of range
Low
$2.33
Current
$2.34
High
$15.15
Company Overviewwww.titanpharm.com

About the company

Titan Pharmaceuticals, Inc. is a pharmaceutical company dedicated to creating treatments for chronic conditions, with its product development centered around ProNeura, a unique platform designed for extended drug release. Currently, the company markets the Probuphine implant in Canada and the European Union.

CEO
Weei Jye Chay
IPO
1996
Employees
4
HQ
Petaling Jaya, KY

Price Chart

-60.56% · this period
$5.30$3.42$1.55Nov 21May 28Jan 12
Valuation
Market Cap
$3.11M
P/E
13334257776718564.00
P/S
2.13
P/B
0.14
EV/EBITDA
-235.70
Div Yield
0.00%
Profitability
Gross Margin
32.98%
Op Margin
8.42%
Net Margin
7.82%
ROE
1.94%
ROIC
0.02%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-2,485,000 · 47.20%
EPS
$-2937.35 · -56063.48%
Op Income
$-2,415,000
FCF YoY
12.01%
Performance & Tape
52W High
$15.15
52W Low
$2.33
50D MA
$4.38
200D MA
$4.05
Beta
1.38
Avg Volume
129.77K

Get TickerSpark's AI analysis on TTNP

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Oct 1, 25Ben-Tzvi Avrahamsell3,313
Oct 1, 25Ben-Tzvi Avrahamsell5,000
Mar 27, 25Loh Gabrielother0
Mar 20, 25Jye Chay Weeiother0
Apr 2, 24Mokhtar Firdauzother0
Apr 2, 24Flores Franciscoother0
Mar 18, 24Choong Choon Hauother54,132
Mar 18, 24Choong Choon Hauother0
Oct 25, 23NATAN DAVIDother16,250
Oct 25, 23McMurdo Matthew Charlesother16,250
Coverage · TTNP

Our TTNP coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on TTNP yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate TTNP report →
Internal Compare

Similar companies

Peers in the same neighborhood.